<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Gameto — Prospect Detail</title>
  <link rel="stylesheet" href="styles.css">
</head>
<body>
<header class="site-header"><h1>Prospect Detail</h1></header>
<div class="container">
  <a href="index.html" class="back-link">&larr; Back to All Prospects</a>
  <div class="detail-header">
    <span class="badge health" style="font-size:.8rem;">Digital Health</span>
    <h1>52. Gameto</h1>
    <p class="meta">IVF and Fertility Innovation</p>
  </div>
  <div class="section"><h3>1. Startup Name</h3><p><strong>Gameto</strong></p></div>
  <div class="section"><h3>2. Founder Contact</h3><p><strong>Wyss Institute Team</strong></p><p>Wyss Institute for Biologically Inspired Engineering at Harvard</p><p>Technology developed through Wyss research programs</p></div>
  <div class="section"><h3>3. Product Overview</h3><p>Gameto is making IVF safer, cheaper, and more accessible through ovarian organoid technology. The company's platform uses lab-grown ovarian support cells to improve egg maturation outside the body, potentially reducing the hormone burden on patients and improving IVF success rates.</p></div>
  <div class="section"><h3>4. Funding Stage</h3><p><strong>Series B</strong> — Raised $40M+ from prominent fertility and biotech investors.</p></div>
  <div class="section"><h3>5. How I Found the Company</h3><p>Discovered through Wyss Institute spinout company portfolio and women's health technology coverage.</p></div>
  <div class="strengths-weaknesses">
    <div class="section"><h3>Strengths</h3><ul><li><strong>Massive market:</strong> IVF market is $25B+ globally with growing demand.</li><li><strong>Patient-friendly:</strong> Reducing hormone load addresses major patient pain point.</li></ul></div>
    <div class="section"><h3>Weaknesses</h3><ul><li><strong>Clinical validation:</strong> Must prove efficacy in human trials before commercialization.</li><li><strong>Regulatory complexity:</strong> Novel cell-based therapies face extended approval timelines.</li></ul></div>
  </div>
  <div class="section"><h3>7. Five Questions for the Team</h3><ol class="questions-list"><li>What is the current stage of your clinical trials?</li><li>How much can you reduce hormone dosing while maintaining success rates?</li><li>What is your go-to-market strategy — partner with clinics or direct sales?</li><li>How do you compare to other IVF innovation companies like Kindbody?</li><li>What is the expected cost reduction for patients using your technology?</li></ol></div>
  <a href="index.html" class="back-link">&larr; Back to All Prospects</a>
</div>
</body>
</html>
